Vyome Therapeutics

About:

Vyome Therapeutics is an innovation driven company, with a vision to develop novel treatments for resistant pathogens

Website: https://www.vyometx.com/

Twitter/X: vyomebio

Top Investors: Perceptive Advisors, Sharrp Ventures, Kalaari Capital, Navam Capital, Iron Pillar

Description:

Vyome Biosciences is an innovation-driven company, with a vision to develop novel drugs for antibiotics-resistant acne and other opportunist pathogens through a unique pipeline of antibiotics that retard resistance development. Vyome’s development platform is completely risk mitigated. Vyome has a deep pipeline of IP based products targeting multiple indications. The *lead molecule (VB 1953)*, which targets the huge unmet need in the drug resistant acne prescription market, will be entering the clinical phase with *USFDA IND Application Filing in Q4 2015*. Vyome has state-of-the-art infrastructure facilities to carry out all its research and lab development work, with full-fledged formulation, analytical, chemistry, biology & molecular biology, clinical and the regulatory divisions. The infrastructure and the team enables Vyome to conceive ideas, develop them and commercialize them at a rapid pace.

Total Funding Amount:

$78.5M

Headquarters Location:

Delhi, Delhi, India

Founded Date:

2010-01-01

Contact Email:

partners(AT)vyome.in

Founders:

Shiladitya Sengupta, Venkateswarlu Nelabhotla

Number of Employees:

11-50

Last Funding Date:

2022-01-01

IPO Status:

Private

Industries:

© 2025 bioDAO.ai